Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase 2b Dose-finding Study to Investigate the Efficacy, Safety and Tolerability of LOU064 in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines
Conditions
Interventions
LOU064 Arm 1
LOU064 Arm 2
+5 more
Locations
82
United States
Novartis Investigative Site
Litchfield Park, Arizona, United States
Novartis Investigative Site
Little Rock, Arkansas, United States
Novartis Investigative Site
Mission Viejo, California, United States
Novartis Investigative Site
San Diego, California, United States
Novartis Investigative Site
Walnut Creek, California, United States
Novartis Investigative Site
Westminster, California, United States
Start Date
June 6, 2019
Primary Completion Date
January 14, 2021
Completion Date
April 15, 2021
Last Updated
April 29, 2022
NCT06931405
NCT06873516
NCT07230418
NCT07219615
NCT05677451
NCT06445023
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions